Checkpoint Inhibitor Refractory Cancer Market Research Report present a detailed analysis of the market listing Checkpoint Inhibitor Refractory Cancer Epidemiology, Drug therapies and pipeline for study period from 2018-2030.

Checkpoint Inhibitor Refractory Cancer Market Size and Share Analysis

DelveInsight's&nbsp;"Checkpoint Inhibitor Refractory Cancer Market Insights, Epidemiology, and Market Forecast-2030"&nbsp;report delivers an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer, historical and forecasted epidemiology as well as the Checkpoint Inhibitor Refractory Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
&nbsp;
The Checkpoint Inhibitor Refractory Cancer market report provides current treatment practices, emerging drugs, Checkpoint Inhibitor Refractory Cancer market share of the individual therapies, current and forecasted Checkpoint Inhibitor Refractory Cancer market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current Checkpoint Inhibitor Refractory Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the&nbsp;Checkpoint Inhibitor Refractory Cancer market.
<h2>Geography Covered</h2>
<ul>
<li>The United States</li>
<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
<li>Japan</li>
</ul>
&nbsp;
Study Period: 2018-2030
<h2>Checkpoint Inhibitor Refractory Cancer Disease Understanding and Treatment Algorithm</h2>
The&nbsp;DelveInsight&rsquo;s&nbsp;Checkpoint Inhibitor Refractory Cancer market report gives a thorough understanding of the Checkpoint Inhibitor Refractory Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
&nbsp;
Checkpoint Inhibitor Refractory Cancer Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Checkpoint Inhibitor Refractory Cancer.
&nbsp;
Checkpoint Inhibitor Refractory Cancer Treatment
It covers the details of conventional and current medical therapies available in the Checkpoint Inhibitor Refractory Cancer market for the treatment of the condition. It also provides Checkpoint Inhibitor Refractory Cancer treatment algorithms and guidelines in the United States, Europe, and Japan.
<h2>Checkpoint Inhibitor Refractory Cancer Epidemiology&nbsp;</h2>
The Checkpoint Inhibitor Refractory Cancer epidemiology&nbsp;section&nbsp;provides insights about the historical and current Checkpoint Inhibitor Refractory Cancer patient pool and forecasted trends for&nbsp;individual&nbsp;seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the&nbsp;Checkpoint Inhibitor Refractory Cancer market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;
&nbsp;
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Checkpoint Inhibitor Refractory Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018 to 2030.
&nbsp;
Country Wise- Checkpoint Inhibitor Refractory Cancer Epidemiology
The epidemiology segment also provides the Checkpoint Inhibitor Refractory Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
<h2>Checkpoint Inhibitor Refractory Cancer Drug Chapters</h2>
The drug chapter segment of the Checkpoint Inhibitor Refractory Cancer report encloses the detailed analysis of Checkpoint Inhibitor Refractory Cancer marketed drugs and late-stage (Phase-III and Phase-II)&nbsp;Checkpoint Inhibitor Refractory Cancer pipeline drugs. It also helps to understand the Checkpoint Inhibitor Refractory Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
&nbsp;
Checkpoint Inhibitor Refractory Cancer Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Checkpoint Inhibitor Refractory Cancer treatment.
&nbsp;
Checkpoint Inhibitor Refractory Cancer Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Checkpoint Inhibitor Refractory Cancer treatment.
<h2>Checkpoint Inhibitor Refractory Cancer Market Outlook</h2>
The Checkpoint Inhibitor Refractory Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Checkpoint Inhibitor Refractory Cancer market trends by analyzing the impact of current&nbsp;Checkpoint Inhibitor Refractory Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Checkpoint Inhibitor Refractory Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Checkpoint Inhibitor Refractory Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Checkpoint Inhibitor Refractory Cancer market in 7MM is expected to witness a major change in the study period 2018-2030.
&nbsp;
Key Findings
This section includes a glimpse of the Checkpoint Inhibitor Refractory Cancer market in 7MM.
&nbsp;
The United States Market Outlook
This section provides the total Checkpoint Inhibitor Refractory Cancer market size and market size by therapies in the United States.
&nbsp;
EU-5 Countries: Market Outlook
The total Checkpoint Inhibitor Refractory Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
&nbsp;
Japan Market Outlook
The total Checkpoint Inhibitor Refractory Cancer market size and market size by therapies in Japan is also mentioned.
<h2>Checkpoint Inhibitor Refractory Cancer Drugs Uptake</h2>
This section focuses on the rate of uptake of the potential Checkpoint Inhibitor Refractory Cancer drugs recently launched in the Checkpoint Inhibitor Refractory Cancer market or expected to get launched in the market during the study period 2018-2030. The analysis covers Checkpoint Inhibitor Refractory Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;
Checkpoint Inhibitor Refractory Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Checkpoint Inhibitor Refractory Cancer market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
&nbsp;
Checkpoint Inhibitor Refractory Cancer Pipeline Development Activities
The&nbsp;Checkpoint Inhibitor Refractory Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Checkpoint Inhibitor Refractory Cancer key players involved in developing targeted therapeutics.
&nbsp;
Pipeline Development Activities
The Checkpoint Inhibitor Refractory Cancer report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Checkpoint Inhibitor Refractory Cancer emerging therapies.
<h2>Reimbursement Scenario in Checkpoint Inhibitor Refractory Cancer</h2>
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
<h2>KOL- Views</h2>
To keep up with current Checkpoint Inhibitor Refractory Cancer market trends, we take KOLs and SMEs ' opinion working in the Checkpoint Inhibitor Refractory Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Checkpoint Inhibitor Refractory Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
<h2>Competitive Intelligence Analysis</h2>
We perform Competitive&nbsp;and Market Intelligence analysis of the Checkpoint Inhibitor Refractory Cancer Market by using various Competitive Intelligence tools that include -&nbsp;SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies&nbsp;etc. The inclusion of the analysis entirely depends upon the data availability.
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of Checkpoint Inhibitor Refractory Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies</li>
<li>Comprehensive insight has been provided into the Checkpoint Inhibitor Refractory Cancer epidemiology and treatment in the 7MM</li>
<li>Additionally, an all-inclusive account of both the current and emerging therapies for Checkpoint Inhibitor Refractory Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape</li>
<li>A detailed review of the Checkpoint Inhibitor Refractory Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM</li>
<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Checkpoint Inhibitor Refractory Cancer market</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>In the coming years, the Checkpoint Inhibitor Refractory Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market</li>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence Checkpoint Inhibitor Refractory Cancer R&amp;D. The therapies under development are focused on novel approaches to treat/improve the disease condition&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Major players are involved in developing therapies for Checkpoint Inhibitor Refractory Cancer. The launch of emerging therapies will significantly impact the Checkpoint Inhibitor Refractory Cancer market</li>
<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Checkpoint Inhibitor Refractory Cancer</li>
<li>Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities</li>
</ul>
<h2>Checkpoint Inhibitor Refractory Cancer Report Insights</h2>
<ul>
<li>Checkpoint Inhibitor Refractory Cancer Patient Population</li>
<li>Therapeutic Approaches</li>
<li>Checkpoint Inhibitor Refractory Cancer Pipeline Analysis</li>
<li>Checkpoint Inhibitor Refractory Cancer Market Size and Trends</li>
<li>Checkpoint Inhibitor Refractory Cancer Market Opportunities</li>
<li>Impact of upcoming&nbsp;Checkpoint Inhibitor Refractory Cancer Therapies</li>
</ul>
<h2>Checkpoint Inhibitor Refractory Cancer Report Key Strengths</h2>
<ul>
<li>11&nbsp;Years Forecast</li>
<li>7MM Coverage</li>
<li>Checkpoint Inhibitor Refractory Cancer Epidemiology Segmentation</li>
<li>Key Cross Competition</li>
<li>Highly Analyzed Market</li>
<li>Drugs Uptake</li>
</ul>
<h2>Checkpoint Inhibitor Refractory Cancer Report Assessment</h2>
<ul>
<li>Current Treatment Practices</li>
<li>Unmet Needs</li>
<li>Checkpoint Inhibitor Refractory Cancer Pipeline Product Profiles</li>
<li>Checkpoint Inhibitor Refractory Cancer Market Attractiveness</li>
<li>Market Drivers and Barriers</li>
</ul>
<h2>Key Questions</h2>
Market Insights:
<ul>
<li>What was the Checkpoint Inhibitor Refractory Cancer drug class share (%) distribution in 2018 and how it would look like in 2030?</li>
<li>What would be the Checkpoint Inhibitor Refractory Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2018-2030)?</li>
<li>What are the key findings pertaining to the market across 7MM and which country will have the largest Checkpoint Inhibitor Refractory Cancer market size during the forecast period (2018-2030)?</li>
<li>At what CAGR, the Checkpoint Inhibitor Refractory Cancer market is expected to grow by 7MM during the forecast period (2018-2030)?</li>
<li>What would be the Checkpoint Inhibitor Refractory Cancer market outlook across the 7MM during the forecast period (2018-2030)?</li>
<li>What would be the Checkpoint Inhibitor Refractory Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?</li>
<li>How would the unmet needs&nbsp;affect the market dynamics and subsequent analysis of the associated trends?</li>
</ul>
Epidemiology Insights:
<ul>
<li>What are the disease risk, burden, and regional/ethnic differences of the Checkpoint Inhibitor Refractory Cancer?</li>
<li>What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What is the historical Checkpoint Inhibitor Refractory Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What would be the forecasted patient pool of Checkpoint Inhibitor Refractory Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Checkpoint Inhibitor Refractory Cancer?</li>
<li>Out of all 7MM countries, which country would have the highest prevalent population of Checkpoint Inhibitor Refractory Cancer during the forecast period (2018-2030)?</li>
<li>At what CAGR the patient population is expected to grow in&nbsp;7MM during the forecast period (2018-2030)?</li>
</ul>
<h2>Current Treatment Scenario, Marketed Drugs and Emerging Therapies:</h2>
<ul>
<li>What are the current options for the Checkpoint Inhibitor Refractory Cancer treatment in addition to the approved therapies?</li>
<li>What are the current treatment guidelines for the treatment of Checkpoint Inhibitor Refractory Cancer in the USA, Europe, and Japan?</li>
<li>What are the Checkpoint Inhibitor Refractory Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?</li>
<li>How many companies are developing therapies for the treatment of Checkpoint Inhibitor Refractory Cancer?</li>
<li>How many therapies are in-development by each company for Checkpoint Inhibitor Refractory Cancer treatment?</li>
<li>How many are emerging therapies in mid-stage, and late stage of development for Checkpoint Inhibitor Refractory Cancer treatment?</li>
<li>What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Checkpoint Inhibitor Refractory Cancer therapies?</li>
<li>What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Checkpoint Inhibitor Refractory Cancer and their status?</li>
<li>What are the current challenges faced in drug development?</li>
<li>What are the key designations that have been granted for the emerging therapies for Checkpoint Inhibitor Refractory Cancer?</li>
<li>What are the global historical and forecasted market of Checkpoint Inhibitor Refractory Cancer?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>The report will help in developing business strategies by understanding trends shaping and driving the Checkpoint Inhibitor Refractory Cancer market</li>
<li>To understand the future market competition in the Checkpoint Inhibitor Refractory Cancer market and Insightful review of the key market drivers and barriers</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for Checkpoint Inhibitor Refractory Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan</li>
<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for Checkpoint Inhibitor Refractory Cancer market</li>
<li>To understand the future market competition in the Checkpoint Inhibitor Refractory Cancer market</li>
</ul>

1. Key Insights
2. Report Introduction
3. Checkpoint Inhibitor Refractory Cancer Market Overview at a Glance
3.1. Patient Share (%) Distribution of Checkpoint Inhibitor Refractory Cancer in 2018
3.2. Patient Share (%) Distribution of Checkpoint Inhibitor Refractory Cancer in 2030
4. Executive Summary of Checkpoint Inhibitor Refractory Cancer
5. Disease Background and Overview
5.1. Introduction
5.2. Scientific Overview
5.3. Cancer-immunity Cycle
5.4. Checkpoint blockade of the CTLA-4 pathway
5.5. Checkpoint blockade of the PD-1/PD-L1
5.6. Next-generation immune checkpoints for cancer therapy
5.7. Solid tumors
5.7.1. Urothelial Carcinoma
5.7.1.1. Diagnosis
5.7.1.2. Treatment
5.7.1.3. Guidelines for Bladder Cancer
5.7.1.4. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.2. NSCLC
5.7.2.1. Pathogenesis
5.7.2.2. Diagnosis
5.7.2.3. Treatment
5.7.2.4. Guideline for NSCLC
5.7.2.4.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021
5.7.2.4.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.3. Melanoma
5.7.3.1. Pathophysiology
5.7.3.2. Diagnosis
5.7.3.3. Treatment
5.7.4. Renal cell carcinoma
5.7.4.1. Pathophysiology
5.7.4.2. Diagnosis
5.7.4.3. Treatment
5.7.4.4. Guidelines for Renal Cell Carcinoma
5.7.4.4.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021
5.7.4.4.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.5. Hodgkin Lymphoma
5.7.5.1. Pathophysiology
5.7.5.2. Diagnosis
5.7.5.3. Treatment
5.7.6. Breast Cancer
5.7.6.1. Pathophysiology
5.7.6.2. Diagnosis
5.7.6.3. Treatment
5.7.7. Cervical Cancer
5.7.7.1. Diagnosis
5.7.7.2. Treatment
5.7.7.3. Guidelines for Cervical Cancer
5.7.7.3.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021
5.7.7.3.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.8. Mesothelioma
5.7.8.1. Pathophysiology
5.7.8.2. Diagnosis
5.7.8.3. Treatment
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Incident Population of Checkpoint-inhibitor refractory patients
6.3. Epidemiology of Checkpoint Inhibitors refractory cancer
6.4. The United States
6.4.1. Incidence by tumor type in the United States
6.4.2. Checkpoint-inhibitor treated patients in the United States
6.4.3. Checkpoint-inhibitor refractory patients in the United States
6.5. EU5
6.5.1. Germany
6.5.1.1. Incidence by tumor type in Germany
6.5.1.2. Checkpoint-inhibitor treated patients in Germany
6.5.1.3. Checkpoint-inhibitor refractory patients in Germany
6.5.2. France
6.5.2.1. Incidence by tumor type in France
6.5.2.2. Checkpoint-inhibitor treated patients in France
6.5.2.3. Checkpoint-inhibitor refractory patients in France
6.5.3. Italy
6.5.3.1. Incidence by tumor type in Italy
6.5.3.2. Checkpoint-inhibitor treated patients in Italy
6.5.3.3. Checkpoint-inhibitor refractory patients in Italy
6.5.4. Spain
6.5.4.1. Incidence by tumor type in Spain
6.5.4.2. Checkpoint-inhibitor treated patients in Spain
6.5.4.3. Checkpoint-inhibitor refractory patients in Spain
6.5.5. United Kingdom
6.5.5.1. Incidence by tumor type in the United Kingdom
6.5.5.2. Checkpoint-inhibitor treated patients in the United Kingdom
6.5.5.3. Checkpoint-inhibitor refractory patients in the United Kingdom
6.6. Japan
6.6.1. Incidence by tumor type in Japan
6.6.2. Checkpoint-inhibitor treated patients in Japan
6.6.3. Checkpoint-inhibitor refractory patients in Japan
7. Organizations contributing towards Checkpoint Inhibitor Refractory Cancer
8. Case Reports
9. Marketed Therapies
10. Checkpoint Inhibitors
10.1. OPDIVO (Nivolumab): Bristol-Myers Squibb
10.1.1. Product Description
10.1.2. Regulatory Milestone
10.1.3. Other Developmental Activities
10.1.4. Pivotal Clinical Trials
10.1.5. Side Effects
10.1.6. Product Profile
10.2. IMFINZI (Durvalumab): AstraZeneca
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Recent Developments
10.2.4. Pivotal Trials
10.2.5. Side effects
10.2.6. Product Profile
10.3. Keytruda (Pembrolizumab): Merck
10.3.1. Product Description
10.3.2. Regulatory Milestone
10.3.3. Recent Developments
10.3.4. Pivotal Clinical Trials
10.3.5. Side Effects of Keytruda
10.3.6. Product Profile
10.4. TECENTRIQ (Atezolizumab): Genentech/Hoffmann-La Roche
10.4.1. Product Description
10.4.2. Regulatory milestone
10.4.3. Other Developmental Activities
10.4.4. Recent Developments
10.4.5. Pivotal Clinical Trials
10.4.6. Side Effects of TECENTRIQ
10.4.7. Product Profile
10.5. Libtayo (Cemiplimab): Regeneron Pharmaceuticals
10.5.1. Product Description
10.5.2. Regulatory Milestone
10.5.3. Recent Developments
10.5.4. Other Development Activities
10.5.5. Pivotal Clinical Trials
10.5.6. Side Effects
10.5.7. Product Profile
10.6. Avelumab (Bavencio): Merck KGaA and Pfizer
10.6.1. Product Description
10.6.2. Regulatory Milestone
10.6.3. Recent Development
10.6.4. Other Development Activities
10.6.5. Pivotal Clinical Trials
10.6.6. Side effects
10.6.7. Product Profile
10.7. YERVOY (Ipilimumab): Bristol-Myers Squibb
10.7.1. Product Description
10.7.2. Regulatory Milestone
10.7.3. Other Developmental Activities
10.7.4. Pivotal Clinical Trials
10.7.5. Side Effects
10.7.6. Product Profile
10.8. Erdafitinib: Janssen Research and Development, LLC
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.7. Safety and Efficacy
10.8.8. Product Profile
11. Emerging Therapies
11.1. Key-Cross: Emerging drugs
11.2. MRx0518: 4D pharma plc.
11.2.1. Drug Description
11.2.2. Other development activities
11.2.3. Clinical Development
11.2.3.1. Clinical trial information
11.2.4. Safety and Efficacy
11.2.5. Product Profile
11.3. Domatinostat (4SC-202): 4SC AG
11.3.1. Drug Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.3.1. Clinical trial information
11.3.4. Safety and Efficacy
11.3.5. Product Profile
11.4. TAVO (Tavokinogene telseplasmid): OncoSec Medical
11.4.1. Drug Description
11.4.2. Other development activities
11.4.3. Clinical Development
11.4.3.1. Clinical trial information
11.4.4. Safety and Efficacy
11.4.5. Product Profile
11.5. Sitravatinib (MG-516): Mirati Therapeutics
11.5.1. Drug Description
11.5.2. Other development activities
11.5.3. Clinical Development
11.5.3.1. Clinical trial information
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.6. APG-115: Ascentage Pharma Group
11.6.1. Drug Description
11.6.2. Other development activities
11.6.3. Clinical Development
11.6.3.1. Clinical trial information
11.6.4. Safety and Efficacy
11.6.5. Product Profile
11.7. ENB003: ENB Therapeutics, Inc.
11.7.1. Drug Description
11.7.2. Other development activities
11.7.3. Clinical Development
11.7.3.1. Clinical trial information
11.7.4. Safety and Efficacy
11.7.5. Product Profile
11.8. Cavrotolimod (AST-008): Exicure, Inc.
11.8.1. Drug Description
11.8.2. Other development activities
11.8.3. Clinical Development
11.7.3.1. Clinical trial information
11.8.4. Safety and Efficacy
11.8.5. Product Profile
11.9. EDP1503: Evelo Biosciences, Inc./Merck Sharp &amp; Dohme Corp.
11.9.1. Product Description
11.9.2. Other Development Activities
11.9.3. Clinical Development
11.9.3.1. Clinical trial information
11.9.4. Safety and Efficacy
11.9.5. Product Profile
11.10. Lenvima (Lenvatinib Mesylate): Eisai
11.10.1. Drug Description
11.10.2. Other development activities
11.10.3. Clinical Development
11.10.3.1. Clinical trial information
11.10.4. Safety and Efficacy
11.10.5. Product Profile
11.11. KRT-232: Kartos Therapeutics
11.11.1. Drug Description
11.11.2. Clinical Development
11.11.2.1. Clinical trial information
11.11.3. Safety and Efficacy
11.11.4. Product Profile
11.12. Cabozantinib: Exelixis
11.12.1. Drug Description
11.12.2. Other Developmental Activities
11.12.3. Clinical Development
11.12.3.1. Clinical trial information
11.12.4. Product Profile
11.13. Anktiva (N-803): ImmunityBio
11.13.1. Drug Description
11.13.2. Other development activities
11.13.3. Clinical Development
11.13.3.1. Clinical trial information
11.13.4. Product Profile
12. Other Promising Therapies
13. Checkpoint Inhibitor Refractory Cancer: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Checkpoint Inhibitor Refractory Cancer in 7MM
13.3. Market Outlook
13.4. United States Market Size
13.4.1. Total Market Size of Checkpoint Inhibitor Refractory Cancer in the United States
13.4.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in the United States
13.5. EU-5 Market Size
13.5.1. Germany
13.5.1.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Germany
13.5.1.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Germany
13.5.2. France
13.5.2.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in France
13.5.2.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in France
13.5.3. Italy
13.5.3.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Italy
13.5.3.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Italy
13.5.4. Spain
13.5.4.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Spain
13.5.4.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Spain
13.5.5. United Kingdom
13.5.5.1. Total market size of Checkpoint Inhibitor Refractory Cancer in the United Kingdom
13.5.5.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in the United Kingdom
13.6. Japan
13.6.1. Total Market size of Checkpoint Inhibitor Refractory Cancer in Japan
13.6.2. Market Size of Checkpoint Inhibitor Refractory Cancer by Therapies in Japan
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Checkpoint Inhibitor Refractory Cancer - Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s Checkpoint Inhibitor Refractory Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understandin..